CD4 and neoplasm: Considering that CD4+ T cells play a key role in tumor immunity and that the inhibition of TCR signaling may affect anti-tumor activity in CD4+ T cells (52), we explored whether PTPRJ could serve as a therapeutic target for enhanced peripheral immunity.